Glyphosate ‘most effective method' for council's weedkilling
The chemical has drawn controversy in recent years amid allegations about possible carcinogenic effects, which continue to be debated and challenged.
In July 2020, a Caerphilly Council officer said the local authority would look at 'suitable alternatives' for weed treatments while using glyphosate.
Five years on, a council spokesperson said Caerphilly 'continues to use glyphosate-based herbicides, which remain licensed in the UK until at least December 2026, pending further review'.
The spokesperson said roadside weedkilling is conducted by a contractor using 'precision spraying technology'.
This is 'currently the most effective method for treating weeds on roads and footpaths', and while 'alternatives exist, they have proven less effective at scale'.
The council also uses glyphosate for countryside management, 'but only as a last resort to treat invasive species such as Japanese knotweed, himalayan balsam, and giant hogweed', the spokesperson explained.
In 'some cases' it is also used in controlled areas for stump treatment or bracken control 'where other options are unavailable'.
The spokesperson said the council 'remains committed to minimising chemical use where possible while maintaining safe and accessible public spaces'.
The council also pointed to a 2022 weedkiller study run by Cardiff Council which trialled a 'highly-concentrated' vinegar, and a hot foam treatment, as possible alternatives to glyphosate.
Following the study, the council said an independent scientific report concluded glyphosate was 'the most effective and sustainable weed control method currently available'.
It was also the 'least expensive product tested and ranked highest for customer satisfaction', Cardiff Council said at the time.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
an hour ago
- Medscape
NICE Urges Ongoing Support After Obesity Treatment
The National Institute for Health and Care Excellence (NICE) has released updated guidance recommending that healthcare providers offer structured, ongoing support to patients after they complete obesity treatment or stop taking weight-loss medications. This includes regular follow-up care, tailored action plans, and social support to help patients maintain their weight loss and avoid regaining weight. New Drugs Raise Need for Long-Term Support The new quality standard comes as weight-loss medications such as semaglutide (Wegovy) and tirzepatide (Mounjaro) are being introduced on the NHS. An estimated 240,000 people are set to be offered tirzepatide over the next 3 years. The update addresses a critical gap in current care, noting that many people regain weight after treatment if they lack adequate support, with consequences for both physical and mental health. In England, 29% of adults are living with obesity and 64% of adults are classified as overweight or obese. Obesity-related illnesses are estimated to cost the NHS £11.4 billion a year and have a wider economic impact of £74.3 billion. Ensuring Continuity of Care The guidance stresses that weight management is a long-term process, not a one-time fix. It recommends that healthcare providers ensure continuity of care by monitoring patients for at least 12 months and offering tailored support to help maintain weight loss. This may include NHS Better Health resources and strategies for habit change, as well as practical adjustments at home or at work. The quality standard advocates for a shift from short-term interventions to strategies that foster lasting behavioural changes. It highlights the importance of self-monitoring and connecting patients with broader support networks, such as online communities, family-led initiatives, and local programmes. Guidance Implementation Professor Jonathan Benger, deputy chief executive of NICE, noted that weight management 'doesn't end when medication stops or when someone completes a behavioural programme,' adding that 'people need structured support to maintain the positive changes they've made.' The new guidance replaces three previous standards and reflects the most up-to-date strategies for tackling obesity through the healthcare system. Healthcare services are advised to begin implementing the standard immediately, with resource impact guidance available to assist in local adaptation.
Yahoo
an hour ago
- Yahoo
Experts reveal potential unintended side effect of Ozempic – and whether we should worry
The use of weight-loss jabs in the UK has skyrocketed, with an estimated 1.5 million people using them. Yet drugs like Ozempic and Wegovy don't just help people lose fat, but potentially muscle too, new research has suggested. A study that tested weight loss jabs on mice found that although muscle mass changes less than expected, muscles still get weaker and tissues like the liver also shrink. Weight-loss injections, also known as GLP-1 receptor agonists, work by mimicking the natural hormone which regulates blood sugar, appetite and digestion. The medications, known as semaglutides, predominantly treat diabetes but are also available on the NHS or via private providers to help adults with a high body mass index (BMI). For example, although Ozempic is used for type 2 diabetes, it is sometimes prescribed off-label as a weight-loss drug. The results of the study, published in the journal Cell Metabolism, revealed Ozempic-induced weight loss decreased muscle mass by about 10 per cent. Most of this lost weight wasn't from skeletal muscles, which surround bones and joints, but instead from other tissues like the liver, which shrank by nearly half. However, because the Ozempic was tested on mice, researchers emphasise that more research is needed to determine whether similar changes to organ size occur in humans and whether those changes come with any risks. 'Loss of mass in metabolically active organs, such as the liver, is expected as part of healthy weight loss,' said Dr Ran Hee Choi, research instructor in nutrition and integrative physiology at the University of Utah college of health, and co-first author on the study. In both mice and humans, weight gain and loss can affect the size of organs like the liver without affecting their function. 'It's unlikely that the observed lean mass loss represents a serious adverse effect,' added Dr Takuya Karasawa, another co-first author on the study. Researchers found some skeletal muscles did shrink by about 6 per cent as the mice lost weight, but not enough to explain the overall muscle loss. However, when someone gains fat, they also tend to gain skeletal muscle. Study authors explain this is because the body needs to work harder to move around. As a result, losing extra fat can lead to a loss of muscle, which will not affect the person's overall quality of life. Researchers also tested the amount of force the mice's muscles exerted and found that some muscle strength decreased as the mice lost weight, even when the size of the muscle stayed roughly the same. This potential loss of strength when taking Ozempic could be a particular concern for adults over the age of 60 who are at a higher risk of muscle loss and reduced mobility. 'The loss of physical function is a strong predictor of not just quality of life but longevity,' added Dr Katsu Funai, professor of nutrition at the University of Utah and the senior author on the study. Dr Funai concluded that further clinical trials of weight loss jabs should check for changes in muscle strength. A spokesperson for Novo Nordisk, which makes Ozempic, said: 'In clinical trial for Wegovy or Ozempic we did not specifically study the medicine's impact on muscle mass. In a sub-study of 140 patients with a BMI of 40 or less, analysis suggested that treatment with Wegovy was accompanied by reductions in both fat and lean body mass, with a greater reduction in fat mass than lean body mass. 'We recommend that any patients experiencing side effects while taking Wegovy or Ozempic contact their healthcare provider.'
Medscape
4 hours ago
- Medscape
Dementia Diagnosis Takes an Average of 3 Years: New Data
TOPLINE: The average time to diagnosis (TTD) of dementia was 3.5 years in a new meta-analysis, with younger age at onset and having frontotemporal dementia consistently associated with even longer diagnostic intervals. METHODOLOGY: This systematic review and meta-analysis used data from 13 cohort studies published up to December 2024. More than 30,000 patients with a diagnosis of dementia were included, with the age at onset ranging between 54 and 93 years. TTD was defined as the interval between the onset of symptoms, rated by family carers or patients using interviews or medical records, and the final diagnosis. TAKEAWAY: A meta-analysis of 10 studies showed the average TTD across all types of dementia was 3.5 years (95% CI, 2.7-4.3), with moderate-quality evidence. An analysis of six studies showed that the average TTD of young-onset dementia was 4.1 years (95% CI, 3.4-4.9), also with moderate-quality evidence. An analysis by dementia type showed consistently longer TTDs for young-onset Alzheimer's disease (TTD, 4.0 years; 95% CI, 2.7-5.2) and frontotemporal dementia (TTD, 4.7 years; 95% CI, 3.0-6.4). In contrast, TTD in late-onset dementia was 2.9 years (95% CI, 2.6-3.2) in analysis of two studies. IN PRACTICE: 'Timely diagnosis of dementia remains a major global challenge, shaped by a complex set of factors, and specific healthcare strategies are urgently needed to improve it,' lead investigator Vasiliki Orgeta, PhD, Division of Psychiatry, University College London, London, England, said in a press release. 'Clinician training is critical to improve early recognition and referral, along with access to early intervention and individualized support, so that people with dementia and their families can get the help they need,' Orgeta added. SOURCE: The study was published online on July 27 in International Journal of Geriatric Psychiatry. LIMITATIONS: Definitions of TTD varied across studies, with different methods used to assess the first symptoms of dementia. The current meta-analysis did not assess factors affecting TTD. Additionally, individuals with severe dementia may not have accurately remembered when they first experienced symptoms, potentially introducing a recall bias. The findings were also not applicable to low- and medium-income countries. DISCLOSURES: The investigators reported having no relevant conflicts of interest. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
